Fig. 1: Suv39h1 deficiency inhibits tumor growth in combination with anti-PD-1 Ab.
From: CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas
A Graphical representation of model system of experimental groups, including littermates WT and Suv39h1-KO mice receiving B16F10-OVA melanoma cells followed by PBS or anti-PD-1 Ab. B Tumor growth kinetics in B16F10-OVA bearing littermate WT and Suv39h1-KO mice receiving PBS or anti-PD-1 Ab. Pooled results from three independent experiments are shown. Numbers refer to rejected tumors out of total mice analyzed. Black arrows indicate time point of initial PBS or anti-PD-1 Ab injection. C Tumor growth kinetics. Data is represented as mean. D Tumor volumes in cm3 (day 20). WT n = 19; WT + aPD-1 n = 16; KO n = 21; KO + aPD-1 n = 16. Pooled results from three independent experiments are shown. E Frequency (%) and quantification (number) of CD8 + TILs (CD45+TCRb+CD4-). WT n = 6; WT + aPD-1 n = 4; KO n = 6; KO + aPD-1 n = 8. A representative experiment out of three is shown. F Representative dot plots showing the frequency of memory and effector CD8 + TILs from B16F10-OVA tumors, frequency (%) and quantification (number). WT n = 6; WT + aPD-1 n = 4; KO n = 6; KO + aPD-1 n = 8. A representative experiment out of three is shown. p values were calculated using two-tailed Mann–Whitney test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. In all graphs, mean±s.e.m. are presented. See also Supplementary Figs. 1 and 2. Source data are provided as a Source Data file.
